
Travere Therapeutics (TVTX) P/E Ratio
P/E Ratio as of Jun 13, 2025: -5.17
Average-5.53
Median-5.46
Minimum-6.26
Maximum-5.17
-5.17
Past Month+2.37 (31.43%)
The P/E ratio for Travere Therapeutics (TVTX) is -5.17 as of Jun 13, 2025. This represents a increase of 37.50% compared to its 12-month average P/E ratio of -3.76. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Travere Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Travere Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Travere Therapeutics to industry peers.
Travere Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Travere Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Travere Therapeutics to industry peers.
Travere Therapeutics (TVTX) P/E Ratio Insights
See Travere Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Travere Therapeutics (TVTX)
Order type
Buy in
Order amount
Est. shares
0 shares
Travere Therapeutics (TVTX) P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jun 2, 2025 | $15.52 | -5.53 |
May 1, 2025 | $20.76 | -5.06 |
Apr 1, 2025 | $17.44 | -4.25 |
Mar 3, 2025 | $19.80 | -4.83 |
Feb 3, 2025 | $20.22 | -4.44 |
Jan 2, 2025 | $18.97 | -4.16 |
Travere Therapeutics (TVTX) End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | -5.17 | +35.34% |
2024 | -3.82 | +87.25% |
2023 | -2.04 | -59.44% |
2022 | -5.03 | -50.97% |
2021 | -10.26 | +27.14% |
2020 | -8.07 | — |
FAQs About Travere Therapeutics (TVTX) P/E ratio
The latest P/E ratio of Travere Therapeutics (TVTX) is -5.17, as of Jun 13, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Travere Therapeutics’s last 12-month average P/E ratio is -3.76, compared to its current P/E ratio of -5.17. This reflects a increase of 37.50%.
Travere Therapeutics’s current P/E ratio of -5.17 is higher than its last 12-month average P/E of -3.76. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Travere Therapeutics’s average P/E ratio over the last 3 years is -3.78. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Travere Therapeutics’s average P/E ratio over the last 5 years is -5.36. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.